Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K E Bremner

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Prostate Cancer and Prostatic Diseases|November 11, 2009
Utility and health-related quality of life in prostate cancer patients 12 months after radical prostatectomy or radiation therapyM D Krahn, K E Bremner, G Tomlinson, et al.
Drugs & Aging|September 1, 1995
Recent advances in geriatric psychopharmacologyC A Naranjo, N Herrmann, N Mittmann, et al.
Prostate Cancer and Prostatic Diseases|October 16, 2013
Predicting utility scores for prostate cancer: mapping the Prostate Cancer Index to the Patient-Oriented Prostate Utility Scale (PORPUS)K E Bremner, N Mitsakakis, L Wilson, et al.
Clinical Pharmacology and Therapeutics|August 1, 1997
Using fuzzy logic to predict response to citalopram in alcohol dependenceC A Naranjo, K E Bremner, M Bazoon, et al.
Clinical Pharmacology and Therapeutics|June 1, 1992
Citalopram decreases desirability, liking, and consumption of alcohol in alcohol-dependent drinkersC A Naranjo, C X Poulos, K E Bremner, et al.
British Journal of Addiction|June 1, 1992
Eating disorders and alcohol abuse in womenD S Goldbloom, C A Naranjo, K E Bremner, et al.
International Clinical Psychopharmacology|September 1, 1994
Fluoxetine attenuates alcohol intake and desire to drinkC A Naranjo, C X Poulos, K E Bremner, et al.
Current Oncology (Toronto, Ont.)|June 19, 2014
Health care costs for prostate cancer patients receiving androgen deprivation therapy: treatment and adverse eventsM D Krahn, K E Bremner, J Luo, et al.
Journal of Clinical Psychopharmacology|February 1, 2000
Long-term benzodiazepine therapy does not result in brain abnormalitiesU E Busto, K E Bremner, K Knight, et al.
Journal of Psychiatry & Neuroscience : JPN|March 20, 1998
Safety of ipsapirone treatment compared with lorazepam: discontinuation effectsU E Busto, C A Naranjo, K E Bremner, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Prostate Cancer and Prostatic Diseases|November 11, 2009
Utility and health-related quality of life in prostate cancer patients 12 months after radical prostatectomy or radiation therapyM D Krahn, K E Bremner, G Tomlinson, et al.
Drugs & Aging|September 1, 1995
Recent advances in geriatric psychopharmacologyC A Naranjo, N Herrmann, N Mittmann, et al.
Prostate Cancer and Prostatic Diseases|October 16, 2013
Predicting utility scores for prostate cancer: mapping the Prostate Cancer Index to the Patient-Oriented Prostate Utility Scale (PORPUS)K E Bremner, N Mitsakakis, L Wilson, et al.
Clinical Pharmacology and Therapeutics|August 1, 1997
Using fuzzy logic to predict response to citalopram in alcohol dependenceC A Naranjo, K E Bremner, M Bazoon, et al.
Clinical Pharmacology and Therapeutics|June 1, 1992
Citalopram decreases desirability, liking, and consumption of alcohol in alcohol-dependent drinkersC A Naranjo, C X Poulos, K E Bremner, et al.
British Journal of Addiction|June 1, 1992
Eating disorders and alcohol abuse in womenD S Goldbloom, C A Naranjo, K E Bremner, et al.
International Clinical Psychopharmacology|September 1, 1994
Fluoxetine attenuates alcohol intake and desire to drinkC A Naranjo, C X Poulos, K E Bremner, et al.
Current Oncology (Toronto, Ont.)|June 19, 2014
Health care costs for prostate cancer patients receiving androgen deprivation therapy: treatment and adverse eventsM D Krahn, K E Bremner, J Luo, et al.
Journal of Clinical Psychopharmacology|February 1, 2000
Long-term benzodiazepine therapy does not result in brain abnormalitiesU E Busto, K E Bremner, K Knight, et al.
Journal of Psychiatry & Neuroscience : JPN|March 20, 1998
Safety of ipsapirone treatment compared with lorazepam: discontinuation effectsU E Busto, C A Naranjo, K E Bremner, et al.
Pageof 3